Systemic availability of Rhinocort Aqua (budesonide) nasal spray: Importance of formulation and definition of delivered dose

Subjects received single doses of intravenous budesonide 400 μg and intranasal budesonide aqueous nasal spray (BANS; Rhinocort Aqua) 400 μg, budesonide via Turbuhaler 800 μg, and budesonide via pressurized metered-dose inhaler (pMDI; Rhinocort Nasal Inhaler) 800 μg in random sequence, with a 6-w...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2002-06, Vol.109 (6), p.1037-1037
Main Authors: O'Dowd, Liza, Thorsson, Lars, Edsbacker, Staffan
Format: Article
Language:English
Subjects:
Administration, Inhalation
Alkalies
Bans
Bronchodilator Agents - administration & dosage
Bronchodilator Agents - pharmacokinetics
Budesonide - administration & dosage
Budesonide - pharmacokinetics
Chemistry, Pharmaceutical
Drug Administration Schedule
Humans
Injections, Intravenous
Toxins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Subjects received single doses of intravenous budesonide 400 μg and intranasal budesonide aqueous nasal spray (BANS; Rhinocort Aqua) 400 μg, budesonide via Turbuhaler 800 μg, and budesonide via pressurized metered-dose inhaler (pMDI; Rhinocort Nasal Inhaler) 800 μg in random sequence, with a 6-week washout period between doses.
ISSN:0091-6749
1097-6825
DOI:10.1067/mai.2002.125260